Syed Abbas Ali

Assistant Professor

20092018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 7 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
B-Cell Maturation Antigen Medicine & Life Sciences
Pentostatin Medicine & Life Sciences
Chimerism Medicine & Life Sciences
Transplants Medicine & Life Sciences
Antigen Receptors Medicine & Life Sciences
Plasmacytoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2009 2018

Bone Marrow Transplantation
Cyclophosphamide
Tissue Donors
Confidence Intervals
Transplants

IQGAP1 scaffold-MAP kinase interactions enhance multiple myeloma clonogenic growth and self-renewal

Gocke, C. B., McMillan, R., Wang, Q., Begum, A., Penchev, V. R., Ali, S. A., Borrello, I., Huff, C. A. & Matsui, W. Nov 1 2016 In : Molecular Cancer Therapeutics. 15, 11, p. 2733-27339 24607 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Phosphotransferases
Growth
Recurrence
Neoplastic Stem Cells

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., Fellowes, V. S., Hakim, F. T., Gress, R. E. & Kochenderfer, J. N. Sep 29 2016 In : Blood. 128, 13, p. 1688-1700 13 p.

Research output: Contribution to journalArticle

B-Cell Maturation Antigen
Antigen Receptors
T-cells
Multiple Myeloma
T-Lymphocytes

Class act: Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma

Burotto, M., Ali, S. A. & O'sullivan Coyne, G. Jan 1 2015 In : Expert Opinion on Drug Safety. 14, 1, p. 97-110 14 p.

Research output: Contribution to journalReview article

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Safety
Phase III Clinical Trials
Expert Testimony

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

Mossoba, M. E. , Halverson, D. C. , Kurlander, R. , Schuver, B. B. , Carpenter, A. , Hansen, B. , Steinberg, S. M. , Ali, S. A. , Tageja, N. , Hakim, F. T. , Gea-Banacloche, J. , Sportes, C. , Hardy, N. M. , Hickstein, D. D. , Pavletic, S. Z. , Khuu, H. , Sabatini, M. , Stroncek, D. , Levine, B. L. , June, C. H. & 6 others Mariotti, J., Rixe, O., Fojo, A. T., Bishop, M. R., Gress, R. E. & Fowler, D. H. Oct 1 2015 In : Clinical Cancer Research. 21, 19, p. 4312-4320 9 p.

Research output: Contribution to journalArticle

Pentostatin
Chimerism
Sirolimus
Cyclophosphamide
Transplants